Korean J Hematol 2003; 38(4):
Published online December 31, 2003
© The Korean Society of Hematology
배성화, 류헌모, 김동완, 김종광, 손상균, 이규보, 도영록, 송홍석, 권기영, 박건욱, 이재련, 이경희, 현명수
대구가톨릭대학교 의과대학 내과학교실,
경북대학교 의과대학 내과학교실
BACKGROUND :
Waldenstrom´s Macroglobulinemia (WM) is a low grade lymphoproliferative disorder that produces monoclonal immunoglobulin M (IgM). Information on the clinical feature and outcome of Korean patients with WM is scanty.
METHODS :
Patients with WM newly diagnosed at 5 university hospitals in Daegu and Gyeongju from 1990 to 2002 were enrolled. Data on 14 patients were retrospectively analyzed.
RESULTS :
The median age at diagnosis was 66 years (range: 48~77) and the male/female ratio was 6:1. All patients except one were symptomatic at presentation. Anemia was observed in all patients and beta2 microglobulin was elevated in 90% of patients. Overall response rate was 45% in the patients treated with alkylating agent and steroid. The median survival of our patients was 39 months (95% confidence interval:13.7~64.3 months) and the only factor associated with poor survival was albumin level by univariate analysis.
CONCLUSION :
Incidence of WM was lower and the median survival of our patients was shorter than that of Western reports. Further studies are needed to confirm prognostic factors and risk adapted treatment guideline of Korean WM patients.
Keywords Waldenstorm's macroglobulinemia, Clinical course, Korea
Korean J Hematol 2003; 38(4): 234-239
Published online December 31, 2003
Copyright © The Korean Society of Hematology.
배성화, 류헌모, 김동완, 김종광, 손상균, 이규보, 도영록, 송홍석, 권기영, 박건욱, 이재련, 이경희, 현명수
대구가톨릭대학교 의과대학 내과학교실,
경북대학교 의과대학 내과학교실
Sung Hwa Bae, Hun Mo Ryoo, Dong Hwan Kim, Jong Kwang Kim, Sang Kyun Sohn, Kyu Bo Lee, Young Rok Do, Hong Suk Song, Ki Young Kwon, Gun Wook Park, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun
Department of Internal Medicine, Daegu Catholic University College of Medicine, Daegu
Kyungpook National University College of Medicine, Daegu, Korea.
BACKGROUND :
Waldenstrom´s Macroglobulinemia (WM) is a low grade lymphoproliferative disorder that produces monoclonal immunoglobulin M (IgM). Information on the clinical feature and outcome of Korean patients with WM is scanty.
METHODS :
Patients with WM newly diagnosed at 5 university hospitals in Daegu and Gyeongju from 1990 to 2002 were enrolled. Data on 14 patients were retrospectively analyzed.
RESULTS :
The median age at diagnosis was 66 years (range: 48~77) and the male/female ratio was 6:1. All patients except one were symptomatic at presentation. Anemia was observed in all patients and beta2 microglobulin was elevated in 90% of patients. Overall response rate was 45% in the patients treated with alkylating agent and steroid. The median survival of our patients was 39 months (95% confidence interval:13.7~64.3 months) and the only factor associated with poor survival was albumin level by univariate analysis.
CONCLUSION :
Incidence of WM was lower and the median survival of our patients was shorter than that of Western reports. Further studies are needed to confirm prognostic factors and risk adapted treatment guideline of Korean WM patients.
Keywords: Waldenstorm's macroglobulinemia, Clinical course, Korea
Ja Min Byun
Blood Res 2023; 58(S1): S11-S12Ju Young Kim, Se Jin Park, Chur Woo You
Blood Res 2021; 56(3): 141-149Hea Lin Oh, Jun Ah Lee, Dong Ho Kim, and Jung Sub Lim
Blood Res 2018; 53(1): 18-24